Abstract
Originalsprog | Engelsk |
---|---|
Tidsskrift | AIDS |
Vol/bind | 22 |
Udgave nummer | 3 |
Sider (fra-til) | 367-76 |
Antal sider | 9 |
ISSN | 0269-9370 |
DOI | |
Status | Udgivet - 2008 |
Bibliografisk note
Keywords: Adult; Anti-HIV Agents; Benzoxazines; Cohort Studies; Drug Resistance, Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment OutcomeAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. / Bannister, Wendy P; Ruiz, Lidia; Cozzi-Lepri, Alessandro; Mocroft, Amanda; Kirk, Ole; Staszewski, Schlomo; Loveday, Clive; Karlsson, Anders; Monforte, Antonella d'Arminio; Clotet, Bonaventura; Lundgren, Jens; Eurosida Study Group.
I: AIDS, Bind 22, Nr. 3, 2008, s. 367-76.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
AU - Bannister, Wendy P
AU - Ruiz, Lidia
AU - Cozzi-Lepri, Alessandro
AU - Mocroft, Amanda
AU - Kirk, Ole
AU - Staszewski, Schlomo
AU - Loveday, Clive
AU - Karlsson, Anders
AU - Monforte, Antonella d'Arminio
AU - Clotet, Bonaventura
AU - Lundgren, Jens
AU - Eurosida Study Group
N1 - Keywords: Adult; Anti-HIV Agents; Benzoxazines; Cohort Studies; Drug Resistance, Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome
PY - 2008
Y1 - 2008
N2 - OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens. METHODS: NNRTI-naive patients were included who started treatment with nevirapine (NVP) or efavirenz (EFV) with genotypic resistance test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after starting the regimen. Cox models were used to investigate time to virological failure (the first of two values). RESULTS: A total of 759 patients were included (13% antiretroviral-naive): 389 initiated NVP and 370 initiated EFV. Baseline IAS-USA NNRTI resistance mutations were detected in 3%. Using the Rega algorithm (version 7.1) to interpret resistance, 460 (64%) patients had resistance (full or intermediate) to at least one drug they were starting (69% NVP, 60% EFV, P = 0.011); 287 (74%) NVP and 168 (45%) EFV patients experienced virological failure after treatment initiation, P < 0.001. After adjustment for previous antiretroviral use, previous AIDS, year started NNRTI, CD4 cell count (baseline, nadir), viral load (baseline, maximum), and baseline drug resistance (measured by Rega), the relative hazards (EFV versus NVP) of virological failure was 0.50, 95% confidence interval: 0.39-0.65, P < 0.001. At time of virological failure, comparable levels of NNRTI resistance were detected. The K103N mutation emerged more in patients failing EFV and Y181C in patients failing NVP. CONCLUSIONS: NVP may be associated with an inferior virological outcome compared to EFV in NNRTI-naive patients with extensive resistance to other drug classes. The profile of NNRTI resistance mutations when virologically failing an NNRTI-containing regimen appears to depend on the NNRTI the patients fail.
AB - OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens. METHODS: NNRTI-naive patients were included who started treatment with nevirapine (NVP) or efavirenz (EFV) with genotypic resistance test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after starting the regimen. Cox models were used to investigate time to virological failure (the first of two values). RESULTS: A total of 759 patients were included (13% antiretroviral-naive): 389 initiated NVP and 370 initiated EFV. Baseline IAS-USA NNRTI resistance mutations were detected in 3%. Using the Rega algorithm (version 7.1) to interpret resistance, 460 (64%) patients had resistance (full or intermediate) to at least one drug they were starting (69% NVP, 60% EFV, P = 0.011); 287 (74%) NVP and 168 (45%) EFV patients experienced virological failure after treatment initiation, P < 0.001. After adjustment for previous antiretroviral use, previous AIDS, year started NNRTI, CD4 cell count (baseline, nadir), viral load (baseline, maximum), and baseline drug resistance (measured by Rega), the relative hazards (EFV versus NVP) of virological failure was 0.50, 95% confidence interval: 0.39-0.65, P < 0.001. At time of virological failure, comparable levels of NNRTI resistance were detected. The K103N mutation emerged more in patients failing EFV and Y181C in patients failing NVP. CONCLUSIONS: NVP may be associated with an inferior virological outcome compared to EFV in NNRTI-naive patients with extensive resistance to other drug classes. The profile of NNRTI resistance mutations when virologically failing an NNRTI-containing regimen appears to depend on the NNRTI the patients fail.
U2 - 10.1097/QAD.0b013e3282f3cc35
DO - 10.1097/QAD.0b013e3282f3cc35
M3 - Journal article
C2 - 18195563
VL - 22
SP - 367
EP - 376
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 3
ER -